» Articles » PMID: 35444165

In-depth Insights into Alzheimer's Disease by Using Explainable Machine Learning Approach

Overview
Journal Sci Rep
Specialty Science
Date 2022 Apr 21
PMID 35444165
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease is still a field of research with lots of open questions. The complexity of the disease prevents the early diagnosis before visible symptoms regarding the individual's cognitive capabilities occur. This research presents an in-depth analysis of a huge data set encompassing medical, cognitive and lifestyle's measurements from more than 12,000 individuals. Several hypothesis were established whose validity has been questioned considering the obtained results. The importance of appropriate experimental design is highly stressed in the research. Thus, a sequence of methods for handling missing data, redundancy, data imbalance, and correlation analysis have been applied for appropriate preprocessing of the data set, and consequently XGBoost model has been trained and evaluated with special attention to the hyperparameters tuning. The model was explained by using the Shapley values produced by the SHAP method. XGBoost produced a f1-score of 0.84 and as such is considered to be highly competitive among those published in the literature. This achievement, however, was not the main contribution of this paper. This research's goal was to perform global and local interpretability of the intelligent model and derive valuable conclusions over the established hypothesis. Those methods led to a single scheme which presents either positive, or, negative influence of the values of each of the features whose importance has been confirmed by means of Shapley values. This scheme might be considered as additional source of knowledge for the physicians and other experts whose concern is the exact diagnosis of early stage of Alzheimer's disease. The conclusions derived from the intelligent model's data-driven interpretability confronted all the established hypotheses. This research clearly showed the importance of explainable Machine learning approach that opens the black box and clearly unveils the relationships among the features and the diagnoses.

Citing Articles

Explainable Artificial Intelligence in Neuroimaging of Alzheimer's Disease.

Taiyeb Khosroshahi M, Morsali S, Gharakhanlou S, Motamedi A, Hassanbaghlou S, Vahedi H Diagnostics (Basel). 2025; 15(5).

PMID: 40075859 PMC: 11899653. DOI: 10.3390/diagnostics15050612.


Support Vector Machine for Stratification of Cognitive Impairment Using 3D T1WI in Patients with Type 2 Diabetes Mellitus.

Xu Z, Zhao L, Yin L, Cao M, Liu Y, Gu F Diabetes Metab Syndr Obes. 2025; 18:435-451.

PMID: 39967716 PMC: 11832351. DOI: 10.2147/DMSO.S480317.


Writing the Signs: An Explainable Machine Learning Approach for Alzheimer's Disease Classification from Handwriting.

Ho N, Gonzalez P, Gogovi G Healthc Technol Lett. 2025; 12(1):e70006.

PMID: 39949642 PMC: 11822997. DOI: 10.1049/htl2.70006.


DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer's disease.

Li V, Han Y, Kaistha T, Zhang Q, Downey J, Gozes I Sci Rep. 2025; 15(1):2093.

PMID: 39814937 PMC: 11735786. DOI: 10.1038/s41598-025-85947-7.


Comparing the Artificial Intelligence Detection Models to Standard Diagnostic Methods and Alternative Models in Identifying Alzheimer's Disease in At-Risk or Early Symptomatic Individuals: A Scoping Review.

Babu B, Parvathy G, Mohideen Bawa F, Gill G, Patel J, Sibia D Cureus. 2025; 16(12):e75389.

PMID: 39781179 PMC: 11709138. DOI: 10.7759/cureus.75389.


References
1.
Meyer M, Tschanz J, Norton M, Welsh-Bohmer K, Steffens D, Wyse B . APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet. 1998; 19(4):321-2. DOI: 10.1038/1206. View

2.
Mudher A, Lovestone S . Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci. 2002; 25(1):22-6. DOI: 10.1016/s0166-2236(00)02031-2. View

3.
Palmqvist S, Janelidze S, Quiroz Y, Zetterberg H, Lopera F, Stomrud E . Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020; 324(8):772-781. PMC: 7388060. DOI: 10.1001/jama.2020.12134. View

4.
Lye T, Shores E . Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychol Rev. 2000; 10(2):115-29. DOI: 10.1023/a:1009068804787. View

5.
Reitz C, Brayne C, Mayeux R . Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7(3):137-52. PMC: 3339565. DOI: 10.1038/nrneurol.2011.2. View